Metronomic chemotherapy treatment (mCHT) refers to the chronic administration of low doses chemotherapy that can sustain prolonged, and active plasma levels of drugs, producing favorable tolerability and it is a new promising therapeutic approach in solid and in hematologic tumors. mCHT has not only a direct effect on tumor cells, but also an action on cell microenvironment, by inhibiting tumor angiogenesis, or promoting immune response and for these reasons can be considered a multi‐target therapy itself. Here we review the state of the art of mCHT use in some classical tumour types, such as breast and no small cell lung cancer (NSCLC), see what is new regarding most recent data in different cancer types, such as glioblastoma (GBL) and acute myeloid leukemia (AML), and new drugs with potential metronomic administration. Finally, a look at the strategic use of mCHT in the context of health emergencies, or in low –and middle‐income countries (LMICs), where access to adequate healthcare is often not easy, is mandatory, as we always need to bear in in mind that equity in care must be a compulsory part of our medical work and research.

Cazzaniga, M., Cordani, N., Capici, S., Cogliati, V., Riva, F., Cerrito, M. (2021). Metronomic chemotherapy. CANCERS, 13(9) [10.3390/cancers13092236].

Metronomic chemotherapy

Cazzaniga M. E.
Primo
;
Cordani N.
Secondo
;
Cerrito M. G.
Ultimo
2021

Abstract

Metronomic chemotherapy treatment (mCHT) refers to the chronic administration of low doses chemotherapy that can sustain prolonged, and active plasma levels of drugs, producing favorable tolerability and it is a new promising therapeutic approach in solid and in hematologic tumors. mCHT has not only a direct effect on tumor cells, but also an action on cell microenvironment, by inhibiting tumor angiogenesis, or promoting immune response and for these reasons can be considered a multi‐target therapy itself. Here we review the state of the art of mCHT use in some classical tumour types, such as breast and no small cell lung cancer (NSCLC), see what is new regarding most recent data in different cancer types, such as glioblastoma (GBL) and acute myeloid leukemia (AML), and new drugs with potential metronomic administration. Finally, a look at the strategic use of mCHT in the context of health emergencies, or in low –and middle‐income countries (LMICs), where access to adequate healthcare is often not easy, is mandatory, as we always need to bear in in mind that equity in care must be a compulsory part of our medical work and research.
Articolo in rivista - Review Essay
Clinical trials; Mechanism of action; Metronomic chemotherapy;
English
2021
13
9
2236
open
Cazzaniga, M., Cordani, N., Capici, S., Cogliati, V., Riva, F., Cerrito, M. (2021). Metronomic chemotherapy. CANCERS, 13(9) [10.3390/cancers13092236].
File in questo prodotto:
File Dimensione Formato  
Cazzaniga-2021-Cancers-VoR.pdf

accesso aperto

Descrizione: Review
Tipologia di allegato: Author’s Accepted Manuscript, AAM (Post-print)
Licenza: Creative Commons
Dimensione 4.21 MB
Formato Adobe PDF
4.21 MB Adobe PDF Visualizza/Apri
10281-401385_VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 4.21 MB
Formato Adobe PDF
4.21 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/401385
Citazioni
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 38
Social impact